Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Trump Buys SpaceX Shares After Record IPO 
California Seeks Paramount Divestitures in Warner Bros. Merger 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Nvidia Options Price in $280 Billion Earnings Swing 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Add as a preferred source on Google
NEW YORK, May 01, 2018 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior to market open on Tuesday, May 8, 2018. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. Eastern Time to discuss the results.
Intercept management will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference at 9:20 a.m. ET on Wednesday, May 9, 2018
- Bank of America Merrill Lynch 2018 Healthcare Conference at 5:00 p.m. PT on Tuesday, May 15, 2018
- UBS Global Healthcare Conference at 3:00 p.m. ET on Monday, May 21, 2018
- Jefferies 2018 Global Healthcare Conference at 9:00 a.m. ET on Friday, June 8, 2018
Webcast information for these events will be available on the investor page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept Pharmaceuticals, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
